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Mineralocorticoid-resistant renal hyperkalemia without salt
wasting (type II pseudohypoaldosteronism): Role of increased
renal chloride reabsorption. A rare syndrome has been described
in which mineralocorticoid-resistant hyperkalemia of renal origin
occurs in the absence of glomerular insufficiency and renal
sodium wasting and in which hyperchioremic acidosis, hyperten-
sion, and hyporeninemia coexist. The primary abnormality has
been postulated to be a defect of the potassium secretory
mechanism of the distal nephron. The present studies were
carried out to investigate the mechanism of impaired renal
potassium secretion in a patient with this syndrome. When
dietary intake of sodium chloride was normal, renal clearance of
potassium was subnormal (CK/GFR = 3.6 0.2%; normal
subjects, 9.0 0.9%, N = 4) despite high normal or supernor-
mal levels of plasma and urinary aldosterone. The fractional
clearance of potassium remained subnormal (CK/GFR = 5.1
0.2%) during superimposed chronic administration of superphys-
iologic doses of mineralocorticoid hormone. Little increase in
renal potassium clearance occurred when the delivery of sodium
to distal nephron segments was increased further by the iv.
infusion of sodium chloride, despite experimentally sustained
hypermineralocorticoidism. But potassium clearance increased
greatly when delivery of sodium to the distal nephron was
increased by infusion of nonchloride anions: sulfate (sodium
sulfate infusion, low sodium chloride diet; CK/GFR = 63.7
0.4%) or bicarbonate (sodium bicarbonate plus acetazolamide
infusion; CK/GFR = 81.7 1.7%). These findings indicate that
mineralocorticoid-resistant renal hyperkalemia in this patient
cannot be attributed to the absence of a renal potassium secre-
tory capability or to diminished delivery of sodium to distal
nephron segments; instead it may be dependent on chloride
delivery to the distal nephron. We suggest that the primary
abnormality in this syndrome increases the reabsorptive avidity
of the distal nephron for chloride, which (1) limits the sodium and
mineralocorticoid-dependent voltage driving force for potassium
and hydrogen ion secretion, resulting in hyperkalemia and acido-
sis and (2) augments distal sodium chloride reabsorption result-
ing in hyperchloremia, volume expansion, hyporeninemia, and
hypertension.
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Hyperkaliemie rénale resistant aux minéralocorticoides sans
perte de sel (pseudohypoaldostéronisme de type II): Role de l'aug-
mentation iie Ia reabsorption de chlore. Un syndrome rare a été
décrit dans lequel une hyperkaliemie d'origine rénale resistant
aux minéralocorticoides survient en l'absence de diminution du
debit de filtration glomerulaire et de perte rénale de sodium et
dans lequel une acidose hyperchioremique, une hypertension et
une hyporéninémie coexistent. L'anomalie primaire qui a été
postulée est un deficit du mécanisme de secretion de potassium
du nephron distal. Ce travail a etC entrepris pour étudier le
mécanisme de Ia modification de Ia secretion rénale de potassium
chez un malade atteint de ce syndrome. Quand l'apport alimen-
taire de chlorure de sodium était normal, Ia clearance rCnale du
potassium était inférieure ala normale (CK/GFR = 3,6 0,2%;
sujets normaux 9,0 0,9%, N = 4) malgré des niveaux a Ia
limite supérieure ou franchement élevCs d'aldostérone plasmati-
que et urinaire. La clearance fractionnelle du potassium était
inférieur a Ia normale (CK/GFR = 5,1 0,2%) au cours de
l'administration de doses supra-physiologiques de minCralocorti-
coIdes. Une augmentation faible de Ia clearance du potassium a
etC observée quand le debit de sodium aux segments distaux du
néphron a été encore augmenté, par l'administration intravein-
euse de chiorure de sodium, malgré l'hyerminéralocorticisme
experimentalement maintenu. La clearance du potassium, ce-
pendant, a considérablement augmenté quand le debit de sodium
au nCphron distal a Cte augmente par Ia perfusion d'anions
différents du chlore: sulfate (perfusion de sulfate de sodium,
régime pauvre en chlorure de sodium: CK/GFR = 63,7 + 0,4%)
ou en bicarbonate (perfusion de bicarbonate de sodium et
perfusion d'acetazolamide: CK/GFR = 83,7 1,7%). Ces
constatations indiquent que l'hyperkaliémie rénale resistant aux
minéralocorticoldes chez ce malade ne peut être attribuée a
l'absence de capacitC secréter le potassium ou a une diminution
du debit de sodium aux segments distaux. Par contre elle peut
dépendre du debit de chiore au nephron distal. Nous suggerons
que l'anomalie initiale dans ce syndrome est une augmentation
de Ia capacité reabsorption du chlore par le nCphron distal qui (1)
limite la force électro-motnce, dépendant du sodium et des
minéralocorticoldes, de secretion des ions hydrogene et potassi-
um, ce qui a pour rCsultat l'hyperkaliemie et l'acidose et (2)
augmente Ia reabsorption distale de chiorure de sodium ce qui a
pour résultat l'hypercholorCmie, l'expansion volémique, l'hy-
poréninemie et l'hypertension.
Chronic hyperkalemia almost always reflects di-
minished renal clearance of potassium such as that
occurring in patients with advanced renal failure.
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Chronic renal hyperkalemia can also occur in pa-
tients in whom the GFR is within the normal range
or only moderately reduced. In some of these
patients (Addison's disease, isolated hypoaldoste-
ronism), renal hyperkalemia can be attributed to a
deficiency of aldosterone [1—4], the major known
hormonal regulator of renal potassium transport 115,
6]. In these patients renal clearance of potassium is
normalized by administration of exogenous mm-
eralocorticoid hormone in physiologic replacement
doses. In other patients with renal hyperkalemia,
aldosterone deficiency is not present, and hyperka-
lemia persists despite administration of even super-
physiologic doses of mineralocorticoids. Such mm-
eralocorticoid-resistant renal hyperkalemia occurs
in two distinctly different clinical syndromes: (1)
classic pseudohypoaldosteronism, characterized by
renal salt wasting and hypotension 117—91 and (2) a
syndrome of chronic mineralocorticoid-resistant
hyperkalemia unaccompanied by renal salt wasting
or hypotension [10—181. We have designated these
syndromes as types I and II pseudohypoaldosteron-
ism, respectively. The primary abnormality in type
I pseudohypoaldosteronism has been postulated to
be a specific defect in the renal response to mm-
eralocorticoid hormone, which accounts for the
coexistence of salt wasting and potassium reten-
tion. The primary abnormality in type II pseudohy-
poaldosteronism has been postulated to be a specif-
ic defect of the renal secretory mechanism for
potassium, which limits the kaliuretic response to
but not the sodium and chloride reabsorptive effect
of mineralocorticoid hormone. The studies reported
herein were carried out to investigate further the
mechanism of impaired renal clearance of potas-
sium in a young adult with type II pseudohypoal-
dosteronism.
Case report
A 23-yr-old white man was admitted to the Clinical Study
Center at San Francisco General Hospital Medical Center on
October 14, 1975, for evaluation of hypertension, hyperkalemia,
and metabolic acidosis. The medical history revealed no abnor-
malities until 1975; in 1973, at the time of completion of military
service, his blood pressure was 136/82 mm Hg. In May 1975, his
blood pressure was found to be 175/120 mm Hg during a routine
physical examination. He denied any significant symptoms ex-
cept for occasional mild headaches. In July 1975, he was
admitted to the Veterans Administration Hospital in San Fran-
cisco. Persistent hyperkalemia (5.3 to 6.0 mEq/liter), hyperchlor-
emia (110 to 113 mEq/liter), and metabolic acidosis (venous total
carbon dioxide 20 to 21 mmoles/liter; arterial pH, 7.35; Pco2, 36
mm Hg) were noted. Creatinine clearance (146 mI/mm) and
urinary excretion of vanillylmandelic acid (6.0 mg124 hr), 17-
hydroxycorticoids (9.1 mg/24 hr), and 17-ketosteroids (16.2
mg/24 hr) were within normal limits. Plasma concentrations of
cortisol (19.0 j.gIdl), testosterone (1314 ngldl), and adrenocorti-
cotropin (59 pg/mI) were also within normal limits. Urinary
excretion of aldosterone-•l8-glucuronide was 14.4 p.g/24 hr (nor-
mal, 5 to 18). Plasma renin activity was undetectable (less than
0.1 ng/ml/hr). At the completion of these studies, the patient was
referred to the Clinical Study Center for further evaluation.
The family medical history revealed that his mother had
hypertension and bronchial asthma. His sister was hypertensive
during pregnancy but is otherwise normotensive. Neither his
mother nor his sister has been noted to be hyperkalemic. His
father has no known medical problems but was unavailable for
examination. The patient smokes I pack of cigarettes per day
and drinks an occasional beer. He admitted to a period of i.v.
drug abuse in 1973 that included heroin and amphetamines.
The patient was well developed and slightly obese. Blood
pressure was 160/106mm Hg supine and 170/116 mm Hg upright.
Mild arteriolar narrowing was noted on funduscopic examina-
tion, but the remainder of the physical examination revealed no
abnormalities.
Hemoglobin was 13.8 g/dl, hematocrit 41.4%, white blood cell
count 5,600/il with a normal differential, and platelet count of
352,000/uI. Urine specific gravity was 1.027; urine protein,
glucose, and acetone were negative; the urinary sediment con-
tained 1 to 2 white blood cells per high power field. Serum
sodium concentration was 140, potassium 5.8, chloride 112
mEq/liter; and total carbon dioxide, 22 mmoles/liter; blood urea
nitrogen was 16; and creatinine, 1.2 mg/dl. Serum concentrations
of calcium, phosphorus, uric acid, bilirubin, cholesterol, fasting
glucose, glutamic-oxaloacetic transaminase, lactic dehydrogen-
ase, creatine phosphokinase, and alkaline phosphatase were
within normal limits. A roentgenogram of the chest and electro-
cardiogram showed no abnormalities.
On this and six subsequent admissions, the patient's disorder
was evaluated extensively. Hyperkalemia (serum potassium, 6.0
0.1 mEq/liter, N = 5) persisted over a period of years and was
partially ameliorated during treatment with hydrochlorothiazide,
50 mg daily (5.0 0.1 mEq/liter, N = 12, P < 0.001) or
furosemide, 40 mg twice daily (5.2 0.2 mEq/liter, N = 5, P <
0.01). Hypertension was also ameliorated during treatment with
diuretic agents.
Methods
All studies were conducted while the patient and
the 14 control subjects (ages 21 to 47 years) were
hospitalized in the Clinical Study Center. Informed
consent was obtained from the patient and the
control subjects after the experimental protocols
were reviewed and approved by the Committee on
Human Research, University of California, San
Francisco.
Evaluation of rena/function. The GFR was esti-
mated by the clearance of endogenous creatinine
and exogenously infused stable iothalamate (Con-
ray 60, Mallinckrodt, St. Louis, Missouri). Renal
concentrating ability was evaluated by a standard
water deprivation protocol [19]. Renal diluting abili-
ty was evaluated during a sustained water diuresis,
obtained by administration of 20 ml of tap water per
kilogram of body weight, orally, followed by an
amount of water equal to urine flow plus 1.0 mI/mm
to replace insensible losses. Renal conservation of
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sodium was evaluated by measurement of the 24-hr
urinary excretion rate of sodium during a 5-day
period in which dietary sodium was restricted to 19
mEq daily. Renal acidification was evaluated by
administration of ammonium chloride, 0.1 g/kg of
body wt [201.
Studies of potassium and acid-base metabolism.
Plasma and urinary electrolyte and acid-base com-
positions were evaluated during metabolic balance
studies in which the patient and five normal control
subjects ingested a constant diet containing 14 to 23
mEg of sodium supplemented by weighed sodium
chloride tablets, 6 g daily. Potassium intake was
also held constant in each study and ranged from
moderately reduced to normal intake levels (0.6 to
1.0 mEq/kg of body wt per day). Control measure-
ments were obtained over a 5-to 7-day period after a
precontrol period of variable duration to permit
equilibration on the metabolic diet. In the patient,
additional measurements were performed in re-
sponse to administration of a cation exchange resin
and in response to treatment with mineralocorticoid
hormone. In the first study, sodium polystyrene
sulfonate (Kayexalate®, Winthrop Laboratories,
New York City), 20 to 30 g daily, was administered
for 7 days. In a separate study, fludrocortisone
acetate (Florinef®, E. R. Squibb and Sons, Prince-
ton, New Jersey) was administered in an initial dose
of 400 g once daily orally for 2 days followed by a
sustaining dose of 200 g daily for 10 days.
Deoxycorticosterone acetate (DOCA) (Percorten®,
CIBA, Summit, New Jersey), 5 mg every 12 hr, was
administered i.m. on days 8 to 10 of fludrocortisone
administration. The dose of fludrocortisone was
then increased to 500 pg once daily, and the patient
was discharged from the hospital; he was then
readmitted for additional measurements on days 46
to 48 of mineralocorticoid therapy.
In separate studies performed under standard
renal clearance conditions, plasma and urinary elec-
trolyte and acid-base levels were evaluated in re-
sponse to the infusion of sodium chloride, sodium
sulfate, and acetazolamide plus sodium bicarbon-
ate. After a steady state of urine flow (V) had been
obtained wherein the values for V for three con-
secutive collection periods were within 1.5 ml/min
of each other, one of the following protocols was
used. (1) The response to the infusion of sodium
chloride was evaluated in the patient and in two
normal subjects after pretreatment with DOCA, 10
mg i.m. 12 and 2 hr before the study. Sodium
chloride, 0.9%, plus sodium bicarbonate, 25 mEq-
/liter, was infused at a rate of 16.7 mi/mm for 120 to
180 mm. (2) The response to infusion of sodium
sulfate was evaluated in the patient and one normal
control subject. These studies were performed after
the patient and normal subject had been maintained
on a restricted sodium chloride intake (less than 20
mEq daily) for 5 days and had been pretreated with
DOCA. 10 mg i.m. 12 and 2 hr before the study.
Sodium sulfate, 0.15 M, plus sodium bicarbonate, 25
mEq/liter, was infused at a rate of 8.3 mI/mm for 2
hr. (3) The response to infusion of acetazolamide
and sodium bicarbonate was compared in two sepa-
rate studies performed before and after treatment
with large doses of mineralocorticoid hormone for 2
weeks (fludrocortisone, 200 pg orally, and DOCA,
10 mg i.m., daily). Before each study, the patient
received sodium bicarbonate, 120 mEq orally, over
a 12-hr period to correct metabolic acidosis. Aceta-
zolamide (Diamox®, Lederle Laboratories, Pearl
River, New York) was infused at a rate of 7.5
mg/mm for 120 to 150 mm, and sodium bicarbonate
(200 mEq/liter) was infused simultaneously at a rate
sufficient to maintain a normal plasma total carbon
dioxide.
Studies of the renin-angiotensin-aldosterone sys-
tem. The response of the renin-angiotensin-aldoste-
rone system to alterations in dietary intake of
sodium and potassium was evaluated in the patient
and compared with values in 11 normal subjects.
Aldosterone production was assessed by measure-
ment of the 24-hr urinary excretion rate of aldoste-
rone-18-glucuronide. In addition, plasma samples
were obtained at 0800 hr after overnight recum-
bency and at 1200 hr after 4 hr of upright activity for
measurement of aldosterone, renin, cortisol, sodi-
um, and potassium concentrations.
Analytic methods. The analytic procedures used
in this laboratory have been described in detail
previously 1121—24]. Plasma renin levels were esti-
mated by radioimmunoassay of angiotensin I gener-
ated in the presence of excess heterologous renin
substrate (plasma renin concentration) [21]. Plasma
and urinary concentrations of iothalamate were
estimated by measurement of iodine concentrations
using fluorescent excitation analysis [251. Estimates
of variation are reported as SEM. Differences
between mean values were compared by Student's t
test [26].
Results
Evaluation of renal function. The GFR and the
renal-concentrating and -diluting abilities in the
patient were within normal limits (Table 1). Renal
conservation of sodium was also normal: urinary
sodium excretion decreased promptly when dietary
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Table 1. Evaluation of renal functiona
GFR
lothalamate clearance, mllminl!.73 m2 130
Creatinine clearance, mlIminIl.73 m2 128
Renal-concentrating ability
Water deprivation (Uommax), m0smlkg 1120 929
Renal-diluting ability
Water loading
U0,, mm, m0sm/kg 1120 38
%VIGFR 14to16
Normal
Patient subjectsb Ref.
a Abbreviations used are Uo,max, maximal urinary osmolality; Uommin, minimal urinary osmolality; V, urinary fiow; and GFR,
glomerular filtration rate.
b Values are the means SEM. Numerals in parentheses indicate range of normal values.
Intake
-----—-
Serum
Table 2. Studies of potassium balancea
Urine Stool
--
UKVK CK C. CKICcr
No. Na K Na K Na K Na K intake
% mi/mm
100
%days
mEq/24 hr mEqlliter mEq/24 hr
Patient
6 122 53 141 5.7 98 37.2
4' 122 53 141 4.8 108 20.7
sodium chloride intake was restricted and was 10.7
mEq/24 hr by the 5th day of salt restriction. Cumu-
lative negative sodium balance was 75 mEq over the
5-day period.
Studies of potassium metabolism. Hyperkalemia
persisted during a steady-state period in which the
intake of potassium was moderately restricted (0.6
mEq/kg body weight per day) and external balance
of potassium was achieved (Table 2). The distribu-
tion of potassium excretion between urine and stool
was abnormal. Fecal excretion of potassium was
abnormally high. When expressed as a function of
dietary intake, urinary excretion of potassium was
abnormally low. Inasmuch as the serum potassium
concentration was supernormal, renal clearance of
potassium was abnormally low. Serum potassium
concentration remained at the upper limits of nor-
mal even when net gastrointestinal absorption of
4.3 17.4 68 4.6 128 3.6
±0.2
76.9 30.5 38 3.0 126 2.2
potassium was reduced to approximately one third
of normal during chronic administration of a cation
exchange resin.
Neither fludrocortisone in doses of 200 to 500
pgIday nor superimposed administration of DOCA,
10 mg daily, corrected the hyperkalemia or substan-
tially increased urinary potassium excretion (Fig.
1). Urinary sodium and chloride excretion, howev-
er, decreased when fludrocortisone was initiated
and again when DOCA administration was superim-
posed.
In renal clearance studies, after pretreatment
with large doses of mineralocorticoid, fractional
potassium clearance remained subnormal when uri-
nary sodium excretion was increased by the infu-
sion of sodium chloride (Fig. 2, left panel). In
contrast, a normal kaliuretic response occurred
when urinary sodium excretion was increased by
132 2
(127 to 140)
74th percentile for age and sex
1068 69
(866 to 1446)
62 2
(40 to 85)
12 I
(8 to 18)
1271
[281
[191
[291
mEq/24 hr
6 120 74 140 4.2
--2
Normal control subjects (N = 4)
115 64.8 1.1 7.1 87 10.6 119 9.0
a Abbreviations used are UKV, urinary potassium excretion; CK, renal clearance of potassium; Cr, renal clearance of creatinine.
Where "±" sign is used, values are the means SEM.b During treatment with sodium polystyrene sulfonate, 10 g three times daily
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Fludrocortisone bicarbonate was 20.8 0.8 mEq/liter under condi-
—05 tions in which the patient was in a steady state while
ingesting a constant diet (mean of five determina-
tions made over a period of 2 yr). The mean values
in the five normal subjects who ingested a diet of
similar composition were pH of 7.42 0.004, Pco,
of 38 2 mm Hg, and bicarbonate concentration of
23.6 1.3 mEq/liter.
During the course of one prolonged balance study
under such steady-state conditions, the mean ve-
nous plasma total carbon dioxide was 24.6 0.5
mmoles/liter and urinary net acid excretion 78 4
mEq/24 hr (0.88 0.04 mEq/kg per 24 hr). The
range of values in the normal subjects for plasma
total carbon dioxide was 26.1 to 29.7 mmoles/liter
and for net acid excretion 0.77 to 1.08 mEq/kg body
weight per 24 hr.
Renal bicarbonate reabsorption was measured
when the plasma bicarbonate concentration was
within normal limits, achieved by oral administra-
tion of sodium bicarbonate, and after chronic cor-
rection of hyperkalemia by oral administration of a
cation exchange resin. Arterial plasma bicarbonate
concentration was 21.9 0.6 mEq/liter, and plasma
potassium concentration was 4.3 0.03 mEq/liter.
The fraction of the filtered load of bicarbonate
excreted (CHCO)/GFR)under these study conditions
was 7.0 0.6% (normal fractional excretion, 1.7
0.5%; normal plasma concentration, 25.1 0.8
mEq/Iiter; N = 5).
In response to the acute administration of ammo-
nium chloride, the minimal value of urine pH was
4.88, and the maximal values of titratable acid,
______ ______
ammonium, and net acid excretion were 0.58, 0.78,
46 and 1.33 jEq/kg body wt per minute, respectively.
This response was not reduced in comparison with
data obtained in normal subjects: urine pH, 4.81
0.06; titratable acid, 0.60 0.05; ammonium, 0.79
0.06; and net acid excretion, 1.39 0.10 pEq/kg
of body wt per minute (N = 5) [201.
In response to the administration of sodium sul-
fate, the urine pH decreased to a minimal value of
4.23, and net acid excretion increased to 101 xEqI
mm, respectively. These values are similar to the
ranges reported for normal subjects [30].
Studies of the renin-angiotensin system. When
the dietary intake of sodium and potassium was
normal, urinary excretion of aldosterone-l8-gluc-
uronide and plasma aldosterone concentrations
were in the upper limits of or above the normal
range (Table 3). Plasma renin concentration was
markedly reduced. When net intake of potassium
was reduced by the administration of a low-potas-
CONTROL 0.41. 0.2
DOCA
75
0
INTAKE
___1_
r NORMAL
B I RANGE
35E
>
B
>
B
>
B
—5 —3 —_1 3 5 10 12
Time, days
Fig. 1. Effect of chronic mineralocorticoid therapy on serum
potassium concentration (SK) and the urinary excretion of
potassium (UKV), sodium (UNV), and chloride (Uc,V) in a
patient with type II pseudohypoaldosteronism.
the infusion of sodium sulfate (Fig. 2, right panel).
Similarly, a brisk kaliuretic response occurred
when sodium excretion was increased by the infu-
sion of acetazolamide and sodium bicarbonate (Fig.
3). In the absence of mineralocorticoid pretreat-
ment, the kaliuretic response to the infusion of
acetazolamide and sodium bicarbonate was mark-
edly blunted (Fig. 3). In all clearance studies, urine
flow in the patient was equal to or greater than that
in normal subjects.
Studies of acid-base metabolism. Arterial blood
pH was 7.38 0.1, Pc02 was 36 1 mm Hg, and
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Urinary sodium excretion, pEq/min
500 1000
Urinary sodium excretion, pEq/min
Fig. 3. Relationship between fractional renal potassium clear-
ance (C/GFR 100) and urinary sodium excretion during infusion
of acetazolamide and sodium bicarbonate in a patient with type
II pseudohypoaldosteronism. The results of two studies are
compared: one in which no prior steroid therapy was given (open
circles) and one in which the patient had been pretreated with
DOCA and fludrocortisone (FHC) for 2 weeks (closed circles).
Fig. 2. Relationship between fractional renal po-
tassium clearance (CKIGFR100) and urinary sodi-
um excretion during infusion of sodium chloride
(left panel) and sodium sulfate (right panel) in a
patient with type II pseudohypoaldosteronism(closed circles) and normal subjects (open sym-
bols). Mineralocorticoid hormone (DOCA, 10 mg
i.m.) was given 12 and 2 hr before the study.
sium diet plus a cation exchange resin, urinary
aldosterone was in the lower limits of or below the
normal range. Corresponding changes were ob-
served in the plasma aldosterone concentration.
When the dietary intake of sodium was reduced,
both urinary aldosterone excretion and plasma
aldosterone concentration increased to values
greater than those observed in control subjects. The
plasma renin concentration also increased but re-
mained at subnormal levels.
Discussion
The occurrence of hyperkalemia in this patient
was, at least in part, of renal origin inasmuch as
under steady-state conditions the urinary excretion
rate of potassium did not exceed that observed in
normokalemic control subjects and did not exceed
the measured net dietary load of potassium (Table
2). These findings exclude the possibility that hy-
perkalemia was due to an increased endogenous or
exogenous systemic load of potassium and impli-
cate reduced renal clearance of potassium as a
significant pathogenetic factor in the maintenance
of hyperkalemia. Based on the assumption that
potassium excreted in the urine normally derives
predominately from potassium secreted by the renal
tubule [311, it can be inferred that the subnormal
renal clearance of potassium in this patient results
from an abnormally reduced rate of secretion of
potassium by the renal tubule.
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Table 3. Summary of hormonal dataa
Urine
Diet
aldosteron
pg/24 hr
e
Posture
PAldo
ng/d!
PRCnin
ng/mI/hr
PNa
,nEq/liter
P1(
Normal Na, normal Kb 23.8
Patient
R
U
14.3
37.5
0.4
0.5
140
137
5.7
6.4
Normal Na, moderately restricted KC 3.2 R
U
11.3
5.2
0.1
0.2
141
141
4.9
4.7
Low Na, normal Kd 65.6 R
U
Norma! control subjects
40.7
93.5
2.7
4.4
132
138
5.1
6.0
Normal Na, normal KC 10.7 R
U
7.9
20.8
4.4
8.7
141
—
4.1
—
Low Na, normal K 27.0 R
U
19.7
57.4
9.8
18.1
143
—
4.5
—
a Abbreviations used are defined as follows: PAIdO, plasma concentration of aldosterone; PRnin, PNa, PK, plasma concentrations of
renin, sodium, and potassium, respectively; R, recumbent; U, upright. Where "±" sign is used, values are the means SEM.
b 120 mEq of sodium, 94 mEq of potassium per 24 hr (N = 3)
C 120 mEq of sodium, 53 mEq of potassium per 24 hr, and during treatment with sodium polystyrene sulfonate
d 18 mEq of sodium, 93 mEq of potassium per 24 hr
a 119 2 mEq of sodium, 75 6 mEq of potassium per 24 hr (N = 11)
20 I mEq of sodium, 76 15 mEq of potassium per 24 hr (N = 4)
Table 4. Summary of findings in reported cases of type II pseudohypoaldosteronisma
Ref.
Age!
sex
yr
Blood
pressure
mm Hg
GFR
mi/mm
(mg/d!)
SNa SK Sa SHCO• .Arterial
pHmEq/!iter
[10—12] 2l/M 180 to 210 116b 143 6.3 to 8.2 107 to 111 18 to 21 7.26
120 to 140
[13] 10/F 160
110
IOOC 140 8.5 117 14 7.30
[141 hIM 110
70
(0.6) 142 7.7 114 16 7.28 to 7.33
[15] 9/M 105
65
106C 140 7.9 108 13 7.25 to 7.37
[16] 52!M
28/F
23/F
200
100
1'
t
130C
(1.0)
(0.8)
138 to 140 5.8 to 6.2
5.8
5.9
106 to 110
108
109
19 to 23 7.30
7.31
7.30
[17] 48/M
21!M
'
120
130 to 150
00b
l23C
139 to 143
136 to 145
5.4 to 6.4
5.2 to 6.2
105 to 109
106 to 112
23 to 27
21 to24
7.36
7.35
lO/M
4/F
90 to 100
110
70
80
60
(0.8)
(1.0)
5.6
5.4
106
lOS
24
23
[18] 33/M 160 to 200 103' 136 to 145 5.8 to 7.6 104 to 109 19 to 26 7.32
9Oto 110
This study 23!M 160
106
l3Ob 140 5.8 112 22 7.38
a Abbreviations used are: GFR, glomerular filtration rate; SNa, 5K etc., serum concentrations of sodium, potassium, etc.; PRA, plasma
renin activity; PAldo, plasma aldosterone concentration; UAIdOV, urinary aldosterone excretion; UNaV, urinary sodium excretion; UKV,
urinary potassium excretion, and UD = undetectable. Values in parentheses are the serum creatinine concentrations because no
measurements of GFR were reported.
b Renal clearance of inulin
C Renal clearance of creatinine
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Despite the administration of superphysiologic
amounts of mineralocorticoids for prolonged peri-
ods of time (Fig. 1), hyperkalemia and subnormal
renal potassium clearance persisted. This finding
distinguishes this patient from patients with adrenal
insufficiency (Addison's disease) in whom hyperka-
lemia is corrected in response to physiologic doses
of mineralocorticoids. The failure of renal potassi-
um clearance to increase in response to administra-
tion of mineralocorticoids in this patient could not
be attributed, however, to a lack of renal respon-
siveness to mine ralocorticoid itself, inasmuch as
the characteristic mineralocorticoid response of an-
tinatriuresis and antichloruresis occurred (Fig. 1).
Furthermore, renal conservation of sodium and
chloride during dietary restriction was not im-
paired. Thus, mineralocorticoid-resistant renal hy-
perkalemia in this patient was not associated with
renal salt wasting, such as occurs in the classic
syndromes of renal mineralocorticoid resistance,
that is, type I pseudohypoaldosteronism [7—91 and
salt-wasting nephritis [32—36]. The additional find-
ings of subnormal plasma renin concentration and
hypertension also distinguish our patient from pa-
tients with Addison's disease and those with classic
mineralocorticoid resistance, which are character-
ized by hyperreninemia secondary to depletion of
extracellular fluid volume and by normal or reduced
blood pressure.
The findings in our patient resemble those that
occurred in a patient described by Paver and Pau-
line lO] and subsequently by Stokes et al [11] and
Arnold and Healy [121 (Table 4). This patient man-
ifested a syndrome characterized by persistent
hyperkalemia in the absence of glomerular insuffi-
ciency, renal sodium wasting, or aldosterone defi-
ciency. Hyperkalemia persisted even when super-
physiologic doses of mineralocorticoids were ad-
ministered. Similar cases with this syndrome have
been reported by other investigators l3—l8] (Table
4). We designated this syndrome as type II pseudo-
hypoaldosteronism to distinguish it from classic
pseudohypoaldosteronism, which we designated as
type I.
Most investigators have postulated that the pri-
mary abnormality in type II pseudohypoaldosteron-
Table 4. (con't.)
ng/ml/hr
'Aldo
ng/dl
'AIdo V
p.g124 hr
Response to mineralocorticoid
-K
(Na2SO4 infusion)
SK response to thiazideAcute
UN,V UKV
.Chronic
SK, mEqiliter
0.7 3.0 36.5 ,
<0.1 2.2 to 3.2 4.0 to 4.5
8.0 to 22.0 6.1 to 6.9 3.4
22.6 6.3 "normal"
UD 8.0 to 30.0 No No 6.0
0.3
0.9
0.5
16.2
47.1
6.5 8.7 1 4.8
0.2 3.5 20.0 f 4.9
<0.1 2.2 to 28.8 23.4 3.5 to 4.0
<0.1 8.9 to 22.5 17.4 to 33.6 4.9 to 5.2 4.6 to 5.3
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ism is a defect in the potassium secretory process in
the distal nephron [12, 14—16, 18]. Such a defect
might account for the renal resistance to mm-
eralocorticoid exemplified by persistent hyperkale-
mia despite normal or increased levels of aldoster-
one, yet permit normal renal responsiveness to
mineralocorticoid exemplified by normal conserva-
tion of sodium during dietary sodium restriction and
a normal sodium reabsorptive response to adminis-
tration of exogenous mineralocorticoid. In our pa-
tient, an intrinsic potassium secretory ability must
exist, inasmuch as renal clearance of potassium
increased normally when distal delivery of sodium
was increased with nonchloride anions, sulfate and
bicarbonate (Figs. 2 and 3). This finding contrasts
with the finding of a distinctly subnormal kaliuretic
response when distal delivery of sodium was in-
creased together with chloride (Fig. 2). Taken to-
gether these findings suggest that an intrinsic potas-
sium secretory ability exists and that the presence
of chloride ion imposes a limitation on the rate of
potassium secretion by the distal nephron.
We postulate that the primary abnormality in our
patient results in an abnormally increased rate of
reabsorption of chloride by the renal tubule. En-
hanced reabsorption of chloride in distal nephron
segments might diminish the normal lumen-negative
transtubular electrical potential difference generat-
ed by active sodium reabsorption and thereby re-
duce the electrical driving force that normally is a
major determinant for potassium secretion in the
distal nephron [37]. Such a "chloride shunt" might
provide an explanation for the finding that renal
clearance of potassium increased normally in our
patient in response to dietary restriction of chloride
and superimposed administration of sodium sulfate
and mineralocorticoid hormone. Based on the re-
sults of micropuncture studies in rats, these experi-
mental conditions would be expected to augment
greatly the transtubular potential difference in lu-
men-negative segments of the distal nephron [38,
39]. Replacement of luminal chloride with a poorly
reabsorbable anion such as sulfate would presum-
ably eliminate an abnormal shunting effect of chlo-
ride on the transtubular potential in the distal neph-
ron. In combination with mineralocorticoid stimula-
tion of sodium reabsorption, elimination of the
chloride shunt might permit generation of sufficient
intraluminal negativity to increase renal potassium
clearance to normal maxima even though the pri-
mary defect of the renal tubule is not corrected.
The occurrence of hyporeninemia and hyperten-
sion in our patient can also be explained as a
consequence of enhanced tubular reabsorption of
chloride. As a result of the reduction in lumen-
negative transtubular potential, the electrical gradi-
ent ordinarily opposing sodium reabsorption would
be diminished and thereby facilitate reabsorption of
sodium and lead to expansion of the extracellular
fluid volume and consequently hypertension and
suppression of renin secretion. If the abnormality of
chloride reabsorption were also present in the mac-
ula densa, hyporeninemia might be a more direct
consequence of enhanced reabsorption of chloride,
inasmuch as chloride reabsorption in the macula
densa appears to have a direct suppressive effect on
renin secretion [40].
The occurrence of hyperchioremic metabolic aci-
dosis in this patient can also be explained as a
consequence of enhanced absorption of chloride.
The occurrence of acidosis was, at least in part, the
result of a reduction in renal hydrogen ion secretion
inasmuch as net acid excretion was not supernor-
mal as would have been expected if the acidosis had
resulted from a chronically increased acid load
[41].' A diminished transtubular potential resulting
from enhanced reabsorption of chloride might re-
duce the electrical driving force for hydrogen ion
secretion as it does for potassium and thereby result
in a subnormal rate of renal hydrogen ion secretion
in the distal nephron. The finding of a highly acidic
urine might be interpreted as evidence against a
reduction in transtubular potential in the distal
nephron. But, in vertebrate species in which the
relationship between transepithelial potential and
hydrogen ion secretion has been studied, elimina-
tion of the transepithelial potential has had little
effect on the maximal hydrogen ion concentration
gradient that can be generated, whereas it substan-
tially reduces the net rate of transepithelial hydro-
gen ion secretion when an opposing hydrogen ion
concentration gradient is not present [43].
Hyperkalemia and hypervolemia may also have
contributed to the pathogenesis of metabolic acido-
sis in our patient. Hyperkalemia is a potential renal
acidosis-producing factor by virtue of its ability to
reduce renal bicarbonate reabsorptive capacity [44]
and to suppress renal production of ammonia [45].
The availability of ammonia for diffusion into the
tubular lumen was reduced in our patient as indicat-
ed by the finding of subnormal urinary ammonium
'The physiologic characteristics of the renal acidification dys-
function in this patient are typical of those in patients with so-
called type 4 renal tubular acidosis [23, 42].
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excretion during chronic acidosis despite highly
acidic urine [23, 46]. Extracellular fluid volume
expansion suppresses renal bicarbonate reabsorp-
tive capacity [44, 47, 48] and may account in part
for the observed reduction in renal bicarbonate
reabsorption measured at normal plasma bicarbon-
ate concentration after sustained correction of hy-
perkalemia.
It is possible that the occurrence of renal hyper-
kalemia and acidosis in this patient is in part a
consequence of hyporeninemia, which imposes a
limitation on aldosterone secretion and consequent-
ly on aldosterone stimulation of renal potassium
and hydrogen ion transport. Although plasma and
urinary aldosterone levels were in the upper limits
of or above the normal range (Table 3), much higher
values would have been expected if plasma renin
levels had not been suppressed, inasmuch as aldos-
terone secretion ordinarily increases in response to
hyperkalemia [49, 50]. This formulation is support-
ed by the finding of a marked increase in aldoster-
one levels when renin secretion was stimulated by
dietary sodium chloride depletion. Presumably,
when salt intake was normal in this patient, the
effect of hyperkalemia to induce hyperaldosteron-
ism was counterbalanced by the lack of the normal
tonic stimulation of aldosterone secretion by the
renin-angiotensin system. The possibility that such
relative hypoaldosteronism contributed to the de-
gree of hyperkalemia is suggested by the finding
that the lowest levels of serum potassium were
observed during chronic treatment with large doses
of mineralocorticoid hormones.2
Gordon et al [13] suggested that hyporeninemia
and hypoaldosteronism in this syndrome occurred
as a consequence of extracellular fluid volume
expansion due to abnormally increased reabsorp-
tion of sodium by the renal tubule proximal to the
aldosterone-responsive segment of the nephron. It
was postulated that sodium balance was reestab-
lished by a "tubular escape mechanism" initiated
and maintained by hypervolemia and that persistent
hyperkalemia was due to aldosterone deficiency.
As previously discussed, aldosterone deficiency
cannot account for the persistence of hyperkalemia
in our patient during treatment with mineralocor-
ticoid hormone (Fig. 1) and for the subnormal
kaliuretic response when delivery of sodium to the
distal nephron was increased further by infusion of
sodium chloride (Fig. 2). The findings in our patient
are compatible with abnormally increased tubular
reabsorption of sodium as suggested by Gordon et
al [13] if it is postulated that the abnormality resides
in the aldosterone-responsive segment of the neph-
ron and is the consequence of an abnormality such
as enhanced renal tubular reabsorption of chloride
that limits potassium-sodium exchange indepen-
dently of the level of aldosterone.
The findings in the present study do not elucidate
the nature of the primary abnormality that leads to
enhanced reabsorption of chloride by the renal
tubule. It is possible that the primary abnormality is
a defect in the transport mechanism for another ion,
such as potassium. A defect in the active electro-
genic component of potassium secretion in the
collecting tubule would be expected to enhance
lumen negativity [37, 52] and thereby increase the
electrical driving force for chloride reabsorption.
Alterations in renal cellular potassium content sec-
ondary to a primary defect in potassium transport
may be accompanied by alterations in cellular me-
tabolism and membrane structure [45, 53, 54] that
conceivably could cause enhancement of chloride
reabsorption. The observation in rats that depletion
of body potassium impairs chloride permeability in
the post macula densa distal nephron [55] raises the
possibility that increased renal cellular potassium
content would have the opposite effect on chloride
transport.
2Although urinary potassium excretion did not increase in re-
sponse to administration of excess mineralocorticoid hormone
(Fig. 1), it is conceivable that fecal potassium excretion in-
creased and thereby accounted for the observed slight ameliora-
tion of hyperkalemia during chronic mineralocorticoid therapy.
In contrast to the lack of a kaliuretic response to mineralocor-
ticoid hormone, an appreciable increase in net acid excretion
occurred but only transiently and of insufficient magnitude to
correct metabolic acidosis. Such mineralocorticoid stimulation
of renal hydrogen ion secretion might occur despite chloride
shunting of the transtubular electrical potential inasmuch as it
has been demonstrated in isolated urinary epithelia that aldoster-
one stimulates hydrogen ion secretion under conditions in which
an increase in both sodium transport and transtubular potential
are prevented from occurring [511.
Acknowledgments
This work was supported in part by U.S. Public Health
Service Research grants HL-11046 and HL-06285 from the
National Heart, Lung and Blood Institute and AM-06415, and
AM-21605 from the National Institute of Arthritis, Metabolism,
and Digestive Diseases. The studies were carried out in the
Clinical Study Center (RR-00083) at San Francisco General
Hospital Medical Center and the General Clinical Research
Center (RR-00079) at the University of California, San Francis-
co, with support by the Division of Research Resources, Nation-
al Institutes of Health.
Reprint requests to Dr. M. Schambelan, Room 310, Building
100, San Francisco General Hospital Medical Center, 1001
Potrero Avenue, San Francisco, California 94110, USA
726 Schambelan et at
References
I. POLLEN RH, WILLIAMS RH: Hyperkalemic neuromyopathy
in Addison's disease. N Engl J Med 263:273—278, 1960
2. BELL H, HAYES WL, VOSBURGH J: Hyperkalemic paralysis
due to adrenal insufficiency. Arch Intern Med 115:418—420,
1965
3. HUDSON JB, CHOBANIAN AV, RELMAN AS: Hypoaldoste-
ronism: a clinical study of a patient with an isolated adrenal
mineralocorticoid deficiency, resulting in hyperkaliemia and
Stokes-Adams attacks. N Eng! J Med 257:529—539, 1957
4. VAGNUCCI AH: Selective aldosterone deficiency. J C/in
Endocrinol Metab 29:279—289, 1969
5. MULROW PJ, FORMAN BH: The tissue effects of mineralo-
corticoids. Am J Med 53:561—572, 1972
6. SHARP GWG, LEAF A: Effects of aldosterone and its mecha-
nism of action on sodium transport, in Handbook of Physiol-
ogy, Section 8, Renal Physiology, edited by ORLOFF J,
BERLINER RW, Washington, D.C., American Physiological
Society, 1973, pp. 815—830
7. CHEEK DB, PERRY JW: A salt wasting syndrome in infancy.
Arch Dis Child 33:252—256, 1958
8. DONNELL GN, LITMAN N, ROLDAN M: Pseudohypo-adren-
alocorticism. Am J Dis Child 97:813—828, 1959
9. ROSLER A, THEODOR R, BlocHis H, GERTY R, ULICK 5,
ALAGEM M, TABACI-INIK E, COHEN B, RABINOWITZ D:
Metabolic responses to the administration of angiotensin II,
K and ACTH in two salt-wasting syndromes. J C/in Endo-
cr/no! Metab 44:292—301, 1977
10. PAVER WKA, PAULINE GJ: Hypertension and hyperpotas-
saemia without renal disease in a young male. Med J Aust
2:305—306, 1964
11. STOKES GS, GENTLE JL, EDWARDS KDG, STEWARD JH:
Syndrome of idiopathic hyperkalaemia and hyper-
tension with decreased plasma renin activity: Ef-
fects on plasma renin and aldosterone of reducing
the serum potassium level. Med J Aust 2:1050—1054,
1968
12. ARNOLD JE, HEALY JK: Hyperkalemia, hypertension and
systemic acidosis without renal failure associated with a
tubular defect in potassium excretion. Am J Med 47:461—
472, 1969
13. GORDON RD, GEDDE5 RA, PAWSEY GK, O'HALLORAN
MW: Hypertension and severe hyperkalaemia associated
with suppression of renin and aldosterone and completely
reversed by dietary sodium restriction. Aust Ann Med 4:287—
294, 1970
14. SPITZER A, EDELMANN CM JR. Goldberg LD, Henneman
PH: Short stature, hyperkalemia and acidosis: A defect in
renal transport of potassium. Kidney mt 3:251—257, 1973
15. WEINSTEIN SF, ALLAN DME, MENDOZA SA: Hyperkale-
mia, acidosis, and short stature associated with a defect in
renal potassium excretion. J Pediatr 85:355—3 58, 1974
16. BRAUTBAR N, LEVI J, ROSLER A, LEITESDORF E, DJALDETI
M, EPSTEIN M, KLEEMAN CR: Familial hyperkalemia, hy-
pertension, and hyporeninemia with normal aldosterone
levels: A tubular defect in potassium handling. Arch Intern
Med 138:607—610, 1978
17. FARFEL Z, IAINA A, ROSENTHAL T, WAKS U, SHIBOLET S,
GAFNI J: Familial hyperpotassemia and hypertension ac-
companied by normal plasma aldosterone levels. Possible
hereditary cell membrane defect. Arch Intern Med 138:1828—
1832, 1978
18. LEE MR, BALL SG, THOMAS TH, MORGAN DB: Hyperten-
sion and hyperkalaemia responding to bendrofluazide. Q J
Med 48:245—258, 1979
19. MILLERM, DALAKOS T, MOSES AM, FELLERMAN H, STREE-
TEN DHP: Recognition of partial defects in antidiuretic
hormone secretion. Ann Intern Med 73:721—729, 1970
20. WRONG 0, DAVIES HEF: The excretion of acid in renal
disease. Q J Med 28:259—313, 1959
21. STOCKIGT JR, COLLINS RD, BIGLIERI EG: Determination of
plasma renin concentration by angiotensin I immunoassay:
Diagnostic import of precise measurement of subnormal
renin in hyperaldosteronism. Circ Res 28 & 29 (Suppl II): 11-
175—191, 1971
22. SCHAMBELAN M, STOCKIGT JR, BIGLIERI EG: Isolated
hypoaldosteronism in adults. A renin-deficiency syndrome.
N EngI J Med 287:573—578, 1972
23. SEBASTIAN A, SCHAMBELAN M, LINDENFELD S, MORRIS
RC JR: Amelioration of metabolic acidosis with fludrocorti-
sone therapy in hyporeninemic hypoaldosteronism. N EngiJ
Med 297:576—583, 1977
24. SCHAMBELAN M, SEBASTIAN A, BIGLIERI EG: Studies of the
prevalance, pathogenesis and functional significance of
aldosterone deficiency in hyperkalemic patients with chronic
renal insufficiency. Kidney mt 17:89—101, 1980
25. GUESRYP, KAUFMAN L, ORLOFF S, NELSON JA, SWANN S,
HOLLIDAY M: Measurement of glomerular filtration rate by
fluorescent excitation of non-radioactive meglumine iothala-
mate. Clin Nephrol 3:134—138, 1975
26. ZAR J: Biostatistical Analysis. Englewood, New Jersey,
Prentice Hall, Inc., 1974
27. ROSENBAUM RW, HRUSKA KA, ANDERSON C, RoBsoNAM,
SLATOPOLSKY E, KLAI-IR S: Inulin: An inadequate marker of
glomerular filtration rate in kidney donors and transplant
recipients? Kidney mt 16:179—186, 1979
28. ROWE JW, ANDRES R, T0BIN JD, NORRISAH, SHOCK NW:
Age-adjusted standards for creatinine clearance.
Ann Intern Med 84:567—569, 1976
29. KLEEMAN CR, EPSTEIN FH, WHITE C: The effect of vari-
ations in solute excretion and glomerular filtration on water
diuresis. J C/in Invest 35:749—756, 1956
30. SELDIN DW, COLEMAN AJ, CARTER NW, RECTOR FC JR:
The effect of Na2SO4 on urinary acidification in
chronic renal disease. J Lab C/in Med 69:893—903, 1967
31. BRENNER BM, BERLINER RW: The transport of potassium,
in Handbook of Physiology, Section 8, Renal Physiology,
edited by ORLOFF J, BERLINER RW, Washington, D.C.,
American Physiological Society, 1973, pp. 497—519
32. THORN GW, KOEPF GF, CLINTON M JR: Renal failure
stimulating adrenocortical insufficiency. N Engi J Med
231:76—85, 1944
33. STANBURY SW, MAHLER RF: Salt-wasting renal disease.
Metabolic observations on a patient with 'salt-losing nephri-
tis." QJ Med 28:425—447, 1959
34. WALKER WG, JOST U, JOHNSON JR, K0wAR5KI A: Meta-
bolic observations on salt wasting in a patient with renal
disease. Am J Med 39:505—519, 1965
35. POPOVTZER MM, KATZ FH, PINGGERA WF, ROBINETTE J,
HALGRIMSON CG, BUTKUS DE: Hyperkalemia in salt-wast-
ing nephropathy: Study of the mechanism. Arch Intern Med
132:203—208, 1973
36. COGAN MC, ARIEFF Al: Sodium wasting, acidosis and
hyperkalemia induced by methicillin interstitial nephritis:
Evidence for selective distal tubular dysfunction. Am J Med
64:500—507, 1978
37. GARCIA-FILHO E, MALNIC G, GIEBISCH G: Effects of
Type II pseudohypoaldosteronism 727
changes in electrical potential difference on tubular potas-
sium transport. Am J Physiol 238:F235—F246, 1980
38. CLAPP JR, RECTOR FC JR, SELDIN D: Effect of unreab-
sorbed anions on proximal and distal transtubular potential
in rats. Am J Physiol 202:781—786, 1962
39. Gimsci-i G, MALNIC G, KLOSE RM, WINDHAGER EE:
Effect of ionic substitutions on distal potential
differences in rat kidney. Am J Physiol 211:560—568,
1966
40. KOTCHEN TA, GALLA JH, LUKE RG: Contribution of chlo-
ride to the inhibition of plasma renin by sodium chloride in
the rat Kidney mt 13:201—207, 1978
41. ELKINTON JR, HUTH EJ, WEBSTER GD JR, MCCANCE RA:
The renal excretion of hydrogen ion in renal tubu-
lar acidosis. Am J Med 29:554—575, 1960
42. SEBASTIAN A, HULTER HN, SCHAMBELAN M: Renal hy-
perchloremic acidosis with hyperkalemia: type 4 renal tubu-
lar acidosis (RTA), in Proceedings of the V!Ith International
Congress of Nephrology, Montreal, edited by BARCELO R,
BERGERON M, CARRIERE S, DIRKS JH, DRUMMOND K,
GUTTMAN RD, LEMLEUX G, MONGEAU J-G, SEELY iF,
BASEL, S. KARGER, 1078, pp. 351—360
43. STEINMETZ PR: Characteristics of hydrogen ion transport in
urinary bladder ui water turtle. J Gun Invest 46:1531—1540,
1967
44. KURTZMAN NA, WHITE MG, ROGERS PW: The effect of
potassium and extracellular volume on renal bicarbonate
reabsorption. Metabolism 22:481—492, 1973
45. TANNEN RL: Relationship of renal ammonia production and
potassium homeostasis. Kidney mt 11:453—465, 1977
46. HULTER HN, ILNICKI LP, HARBOTTLE JA, SEBASTIAN A:
Impaired renal H secretion and NH3 production in
mineralocorticoid-deficient glucocorticoid-replete dogs. Am
J Physiol 232:Fl36—F146, 1977
47. KURTZMAN NA: Regulation of renal bicarbonate reabsorp-
tion by extracellular volume. J Clin Invest 49:586—595, 1970
48. SLAT0POLSKY E, HOFFSTEN P, PURKERSON M, BRICKER
NS: On the influence of extracellular fluid volume expansion
and of uremia on bicarbonate reabsorption in man. J Clin
Invest 49:988—998, 1970
49. DLUHY RG, AXELROD L, UNDERWOOD RH, WILLIAMS GH:
Studies of the control of plasma aldosterone con-
centration in normal man: II. Effect of dietary
potassium and acute potassium infusion. J Gun Invest
51:1950—1957, 1972
50. HIMATHONGKAM T, DLUHY RG, WILLIAMS GH: Potassium-
aldosterone-renin interrelationships. J Gun Endocrinol Me-
tab 41:153—159, 1975
51. AL-AWQATI Q, NORBY LH, MUELLER A, STEINMETZ PR:
Characteristics of stimulation of H * transport by
aldosterone in turtle urinary bladder. J Clin Invest 58:351—
358, 1976
52. BOUDRY iF, STONER LC, BURG MB: Effect of acid lumen
pH on potassium transport in renal cortical collecting tu-
bules. Am J Physiol 230:239—244, 1976
53. MORRIS Di, DOUGLIS F, DECONTI G: Effect of potassium
loading on metabolism of aldosterone in rats. Metabolism
27:737—744, 1978
54. OrOriEz NG, TOBACK FG, AITHAL HN, SPARGO BH:
Zonal changes in renal structure and phospholipid
metabolism during reversal of potassium depletion
nephropathy. Lab Invest 36:33—47, 1977
55. LUKE RU, WRIGHT FS, FOWLER N, KASHGARIAN M, GIE-
BISCH GH: Effects of potassium depletion on renal tubular
chloride transport in the rat. Kidney mt 14:414—427, 1978
